Armata Pharmaceuticals, Inc. (ARMP)

NYSEAMERICAN: ARMP · USD

$3.27

-0.22 (-6.3%)· Recorded snapshot

Market cap	121.6M
Revenue (ttm)	5.5M
Net income (ttm)	-192.2M
EPS (ttm)	-$5.27
Shares out	37.2M
Volume	55,768
Beta	1.41

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 5.5M
Net income (ttm): -192.2M
EPS (ttm): -$5.27
Market cap: 121.6M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROIC-28.1

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ARMP indicators

Market & fundamental data

Available fields

193

Groups with data

Currency

USD

Showing 193 of 193 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000921114
Company name	Armata Pharmaceuticals, Inc.
Country	United States
Country code	US
CUSIP number	04216R102
Earnings date	2026-11-11
Earnings time	amc
Employees	61
Employees change	1
Employees growth	1.67%
Enterprise value	$411.6M
Exchange	NYSEAMERICAN
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
In index	RUSSELL2000
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US04216R1023
Last 10-K release date	2026-03-25
Last earnings date	2026-08-12
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$121.6M
Market cap category	Micro-Cap
Next earnings date	2026-11-11
Options	Yes
Price	$3.27
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	ARMP
U.S. state	California
Website	https://www.armatapharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-161.18%
EV/Sales	75.73x
FCF / EV yield	-6.14%
FCF yield	-19.88%
Forward EV/Sales	434.99x
Forward P/S	134.47x
P/S ratio	23.41x
Sector forward P/E	23.53x
Sector P/E	51.01x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	-217.36%
Operating margin	-636.55%
Pretax margin	-3,467.04%
Profit per employee	$-3.2M
Profitable quarters	1
Revenue per employee	$90,869
ROA	-25.83%
ROA (5Y)	-26.81%
ROCE	22.02%
ROIC	-28.05%
SBC / revenue	103.19%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	0
Net income growth quarters	1
Net income growth years	0
Revenue growth	-19.29%
Revenue growth (Q)	15.72%
Revenue growth (QoQ)	218.12%
Revenue growth 3Y	10%
Revenue growth 5Y	12.87%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-374,000
Depreciation and amortization	$1.8M
EBIT	$-35.3M
EBITDA	$-33.4M
EPS	$-5.27
FCF per share	$-0.69
Financing cash flow	$44.1M
Free cash flow	$-25.8M
Free cash flow minus SBC	$-31.5M
Gross profit	$-12M
Investing cash flow	$-374,000
Net borrowing	$40M
Net cash flow	$18.4M
Net income	$-192.2M
Operating cash flow minus SBC	$-31.1M
Operating income	$-35.3M
Revenue	$5.5M
Stock-based compensation	$5.7M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-12.22
Book value per share	$-6.22
Goodwill	$3.5M
Interest coverage	-1.65
Long-term assets	$62.8M
Long-term liabilities	$70.9M
Net cash (debt)	$-290M
Net cash / market cap	-223.48%
Piotroski F-Score	2
Property, plant and equipment	$44.1M
Shareholders' equity	$-231.2M
Tangible book value	$-234.7M
Tangible book value per share	$-6.32
Total assets	$90M
Total cash	$24M
Total debt	$314M
Total liabilities	$321.1M
WACC	7.32%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.06
Current assets	$27.2M
Current liabilities	$250.2M
Current ratio	0.11
Net working capital	$-888,000
Quick ratio	0.11
Working capital	$-223M
Working capital turnover	-0.03

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-0.77%
Dividend yield	0%
Shareholder yield	-0.77%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$6.52
1D price change	-6.3%
1M price change	-12.57%
1M total return	-12.57%
1W price change	6.86%
1W total return	6.86%
1Y price change	-37.95%
1Y return CAGR	-37.97%
1Y total return	-37.95%
20-day SMA	$3.41
200-day SMA	$7.04
3M price change	-36.5%
3M total return	-36.5%
3Y price change	58.74%
3Y return CAGR	16.65%
3Y total return	58.74%
50-day SMA	$4.24
50-day SMA vs 200-day SMA	50under200
52-week high	$14.98
52-week high date	2026-04-22
52-week low	$2.75
52-week low date	2026-10-14
5Y price change	10.47%
5Y return CAGR	2.01%
5Y total return	10.47%
6M price change	-70.27%
6M total return	-70.27%
All-time high	$16.34
All-time high date	2025-10-22
All-time low	$0.83
All-time low date	2022-12-28
Average true range (ATR)	$0.40
Average volume	101K
Beta (1Y)	0.39
Beta (2Y)	0.45
Beta (5Y)	1.41
Change from 52-week high	-78.17%
Change from 52-week low	19.13%
Change from all-time high	-79.99%
Change from all-time low	293.45%
Change from open	-1.51%
Day's gap	-4.87%
Dollar volume	$182,361
High price	$3.36
Low price	$3.26
Monthly RSI	43.71
Open price	$3.32
Position in 52-week range	14.29%
Premarket change	6.88%
Premarket close	$3.49
Premarket price	$3.73
Previous close	$3.49
Price vs 150-day SMA	-49.88%
Price vs 20-day SMA	-4.16%
Price vs 200-day SMA	-53.56%
Price vs 50-day SMA	-22.93%
Relative volume	0.55
RSI	43.52
Sharpe ratio	0.1
Sharpe ratio (3Y)	0.62
Sharpe ratio (5Y)	0.48
Sortino ratio	0.2
Sortino ratio (3Y)	1.24
Sortino ratio (5Y)	0.92
Volume	55.8K
Weekly RSI	35.36
YTD price change	-47.93%
YTD total return	-47.93%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	11.9M
Float percentage	32.01%
Shares change (QoQ)	69.84%
Shares change (YoY)	0.77%
Shares held by insiders	0.55%
Shares held by institutions	13.52%
Shares outstanding	37.2M
Short % of float	8.1%
Short % of shares	2.59%
Short ratio	2.8 days

Deeper analysis on ARMP

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ARMP report

Is a complete ARMP research report available?

No complete published report is available for Armata Pharmaceuticals, Inc. (ARMP) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Armata Pharmaceuticals, Inc. (ARMP)

Price

Financial snapshot

Fair-value bridge

Latest news · ARMP

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ARMP indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ARMP

Frequently asked questions